Darya-Varia Laboratoria Tbk PT
IDX:DVLA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 390
1 810
|
Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Darya-Varia Laboratoria Tbk PT
Free Cash Flow
Darya-Varia Laboratoria Tbk PT
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
Free Cash Flow
Rp207.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
||
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
Free Cash Flow
Rp1.2T
|
CAGR 3-Years
35%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
Kalbe Farma Tbk PT
IDX:KLBF
|
Free Cash Flow
Rp3.3T
|
CAGR 3-Years
12%
|
CAGR 5-Years
25%
|
CAGR 10-Years
20%
|
||
Soho Global Health Tbk PT
IDX:SOHO
|
Free Cash Flow
Rp155.5B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Pyridam Farma Tbk PT
IDX:PYFA
|
Free Cash Flow
Rp75.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
55%
|
CAGR 10-Years
55%
|
||
Kimia Farma Tbk PT
IDX:KAEF
|
Free Cash Flow
Rp87.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-6%
|
Darya-Varia Laboratoria Tbk PT
Glance View
PT Darya-Varia Laboratoria Tbk engages in the manufacture and trade of pharmaceutical products and cosmetics. The company is headquartered in Jakarta, Dki Jakarta and currently employs 1,274 full-time employees. Its segments include prescription drugs, consumer health products, and export and toll manufacturing services. The firm provides products and services for consumer health, skin nutrition, respiratory, vitamins and daily relief. The Company’s products include Remscar (silicone gel), Carvilol, Ondavar (antiemetic), Etorix, Forti-D (vitamin D supplement), Decolgen, Neozep, Stop Cold, Decolsin, and Allerin. The Carvilol is used for heart health and treating hypertension. Ondavar is an antiemetic product used for nausea and vomiting during pregnancy. Etorix is a pain reliever. Forti-D is a supplement to fulfill the body’s need for vitamin D3. Darya-Varia provides a range of brands such as Enervon-C, Enervon Active, and Supertin that helps to boost body immune and maintain health. The firm also provides Imunped as supplement for kids with Zinc and vitamin C for children.
See Also
What is Darya-Varia Laboratoria Tbk PT's Free Cash Flow?
Free Cash Flow
207.9B
IDR
Based on the financial report for Sep 30, 2024, Darya-Varia Laboratoria Tbk PT's Free Cash Flow amounts to 207.9B IDR.
What is Darya-Varia Laboratoria Tbk PT's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
4%
Over the last year, the Free Cash Flow growth was 135%. The average annual Free Cash Flow growth rates for Darya-Varia Laboratoria Tbk PT have been 10% over the past three years , 4% over the past five years .